<DOC>
	<DOCNO>NCT01978171</DOCNO>
	<brief_summary>The investigator determine factor predictive development severity everolimus-induced interstitial lung disease develop prediction model base risk factor .</brief_summary>
	<brief_title>Prediction Everolimus-induced Interstitial Lung Disease</brief_title>
	<detailed_description>In study investigator prospectively investigate pulmonary adverse event treatment everolimus . The investigator distinguish follow everolimus-induced pulmonary adverse event : pulmonary infection , everolimus-induced airway disease everolimus-induced interstitial lung disease ( ILD ) . The investigator investigate predictive value pneumoproteins , everolimus exposure , pulmonary function test , four distinct radiological pattern , baseline patient characteristic development skin toxicity oral mucositis development severity everolimus-induced ILD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult woman metastatic locally advanced breast cancer amenable curative treatment surgery radiotherapy . Histological cytological confirmation estrogenreceptor positive ( ER+ ) breast cancer Postmenopausal woman Radiological clinical evidence recurrence progression last systemic therapy prior enrollment Resistance treatment nonsteroidal aromatase inhibitor Serum platelets â‰¥ 100x10E9/l Everolimus dose adjustment recommend patient hepatic impairment ( ChildPugh A/B/C ) Performance status ECOG 0 2 ( Karnofsky index : 60 100 ) Patients HER2overexpressing tumor Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) . Patients known history HIV seropositivity hepatitis B C Uncontrolled diabetes mellitus Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast neoplasm</keyword>
	<keyword>everolimus</keyword>
	<keyword>interstitial lung disease</keyword>
	<keyword>pneumonitis</keyword>
</DOC>